Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma

American Journal of Respiratory Medicine

Volumn 1, Issue 3, 2002, Pages 185-193

  Corry, David B ^a   Kheradmand, Farrah ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; JANUS KINASE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; PROTEIN TYROSINE KINASE; RECEPTOR SUBUNIT; STAT6 PROTEIN; TRANSCRIPTION FACTOR;

AIRWAY DYNAMICS; ALLERGIC ASTHMA; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CLINICAL STUDY; CYTOPLASM; DRUG EFFICACY; EFFECTOR CELL; EXPERIMENTAL MODEL; FEASIBILITY STUDY; GOBLET CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MAST CELL; METAPLASIA; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT PLANNING;

EID: 0041629644     PISSN: 11756365     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256608     Document Type: Review

References (103)

1. Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in near-fatal asthma. N Engl J Med 1991; 324 (5): 285-8
2. Van Schayck CP, Dompeling E, Van Herwaarden CL, et al. Interacting effects of atopy and bronchial hyperresponsiveness on the annual decline in lung function and the exacerbation rate in asthma. Am Rev Respir Dis 1991; 144 (6): 1297-301
3. Pare PD, Bai TR, Roberts CR. The structural and functional consequences of chronic allergic inflammation of the airways. Ciba Found Symp 1997; 206: 71-86; discussion 86-9, 106-10
4. Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984; 39 (2): 131-6
5. Backman KS, Greenberger PA, Patterson R. Airways obstruction in patients with long-term asthma consistent with 'irreversible asthma'. Chest 1997; 112 (5): 1234-40
6. Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999; 402 (6760 Suppl.): B18-23
7. Kidney JC, Wong AG, Efthimiadis A, et al. Elevated B cells in sputum of asthmatics. Close correlation with eosinophils. Am J Respir Crit Care Med 1996; 153 (2): 540-4
8. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326 (5): 298-304
9. Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 1996; 154 (1): 224-30
10. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154 (5): 1505-10
11. Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997; 158 (7): 3539-44
12. Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against 'intrinsic' asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154 (5): 1497-504
13. Gratziou C, Carroll M, Montefort S, et al. Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. Am J Respir Crit Care Med 1996; 153 (2): 515-20
14. Bradley BL, Azzawi M, Jacobson M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88 (4): 661-74
15. Shimura S, Andoh Y, Haraguchi M, et al. Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur Respir J 1996; 9 (7): 1395-401
16. Aikawa T, Shimura S, Sasaki H, et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101 (4): 916-21
17. Hogg JC. The pathology of asthma. APMIS 1997; 105 (10): 735-45
18. Busse WW, Coffman RL, Gelfand EW, et al. Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. Am J Respir Crit Care Med 1995; 152 (1): 388-93
19. Krinzman SJ, De Sanctis GT, Cernadas M, et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996; 99 (12): 2693-9
20. Van Oosterhout AJ, Hofstra CL, Shields R, et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997; 17 (3): 386-92
21. Gavett SH, Chen X, Finkelman F, et al. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 1994; 10: 587-93
22. Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183 (1): 109-17
23. Corry DB, Grunig G, Hadeiba H, et al. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol Med 1998; 4 (5): 344-55
24. Watanabe A, Mishima H, Kotsimbos TC, et al. Adoptively transferred late allergic airway responses are associated with Th2-type cytokines in the rat. Am J Respir Cell Mol Biol 1997; 16 (1): 69-74
25. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282 (5397): 2261-3
26. Madden KB, Urban Jr JF, Ziltener HJ, et al. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol 1991; 147 (4): 1387-91
27. Finkelman FD, Katona IM, Urban Jr IF, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988; 141 (7): 2335-41
28. Snapper CM, Finkelman FD, Paul WE. Differential regulation of IgG1 and IgE synthesis by interleukin 4. J Exp Med 1988; 167 (1): 183-96
29. Finkelman FD, Katona IM, Urban Jr JF, et al. Control of in vivo IgE production in the mouse by interleukin 4. Ciba Found Symp 1989; 147: 3-17; discussion 17-22
30. Coffman RL, Seymour BW, Hudak S, et al. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989; 245 (4915): 308-10
31. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282 (5397): 2258-61
32. Obiri NI, Debinski W, Leonard WJ, et al. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995; 270 (15): 8797-804
33. Lefort S, Vita N, Reeb R, et al. IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells. FEBS Lett 1995; 366 (2-3): 122-6
34. Smerz-Bertling C, Duschl A. Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor. J Biol Chem 1995; 270 (2): 966-70
35. Murata T, Puri RK. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell Immunol 1997; 175 (1): 33-40
36. Orchansky PL, Ayres SD, Hilton DJ, et al. An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. J Biol Chem 1997; 272 (36): 22940-7
37. Palmer-Crocker RL, Hughes CC, Pober JS. IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. J Clin Invest 1996; 98 (3): 604-9
38. Kopf M, Le GG, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362 (6417): 245-8
39. Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000; 165 (1): 108-13
40. Blease K, Jakubzick C, Westwick J, et al. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol 2001; 166 (8): 5219-24
41. Kamogawa Y, Minasi LE, Carding SR, et al. The relationship of IL-4- and IFNg-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 1993; 75: 985-95
42. Noben-Trauth N, Shultz LD, Brombacher F, et al. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci U S A 1997; 94 (20): 10838-43
43. Dent AL, Hu-Li J, Paul WE, et al. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci U S A 1998; 95 (23): 13823-8
44. Gauchat JF, Schlagenhauf E, Feng NP, et al. A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol 1997; 27 (4): 971-8
45. Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4 (3): 313-9
46. Hoshino T, Winkler-Pickett RT, Mason AT, et al. IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. J Immunol 1999; 162 (1): 51-9
47. Burd PR, Thompson WC, Max EE, et al. Activated mast cells produce interleukin 13. J Exp Med 1995; 181 (4): 1373-80
48. Hancock A, Armstrong L, Gama R, et al. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mot Biol 1998; 18 (1): 60-5
49. McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998; 9 (3): 423-32
50. Walter DM, Mcintire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001; 167: 4668-75
51. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15 (1): 19-26
52. Hilton DJ, Zhang JG, Metcalf D, et al. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci U S A 1996; 93 (1): 497-501
53. Donaldson DD, Whitters MJ, Fitz L, et al. The routine IL-13Ra2: molecular cloning, characterization and comparison with murine IL-13Ra1. J Immunol 1998; 161 (5): 2317-24
54. Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380 (6575): 630-3
55. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254 (5032): 707-10
56. Grunewald SM, Werthmann A, Schnarr B, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998; 160 (8): 4004-9
57. Morawetz RA, Gabriele L, Rizzo LV, et al. Interleukin (IL)-4-independent immunoglobulin class switch to immunoglobulin (Ig)E in the mouse. J Exp Med 1996; 184 (5): 1651-61
58. Emson CL, Bell SE, Jones A, et al. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med 1998; 188 (2): 399-404
59. McKenzie GJ, Fallon PG, Emson CL, et al. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999; 189 (10): 1565-72
60. Chiaramonte MG, Schopf LR, Neben TY, et al. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999; 162 (2): 920-30
61. Newlands GF, Miller HR, MacKellar A, et al. Stem cell factor contributes to intestinal mucosal mast cell hyperplasia in rats infected with Nippostrongylus brasiliensis or Trichinella spiralis, but anti-stem cell factor treatment decreases parasite egg production during N brasiliensis infection. Blood 1995; 86 (5): 1968-76
62. Townsend JM, Fallon GP, Matthews JD, et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000; 13 (4): 573-83
63. Temann UA, Geba GP, Rankin JA, et al. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998; 188 (7): 1307-20
64. Renauld JC, Kermouni A, Vink A, et al. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukoc Biol 1995; 57 (3): 353-60
65. Nilsson G, Nilsson K. Effects of interleukin (IL)-13 on immediate-early response gene expression, phenotype and differentiation of human mast cells. Comparison with IL-4. Eur J Immunol 1995; 25 (3): 870-3
66. Seder RA, Paul WE, Ben SS, et al. Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils. Int Arch Allergy Appl Immunol 1991; 94 (1-4): 137-40
67. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10 (5): 471-80
68. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 176 (5): 1381-6
69. Hogan SP, Mould A, Kikutani H, et al. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest 1997; 99 (6): 1329-39
70. Brusselle G, Kips J, Joos G, et al. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 1995; 12 (3): 254-9
71. Hogan SP, Matthaei KI, Young JM, et al. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 1998; 161: 1501-9
72. Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol 1998; 161: 3813-6
73. Corry DB. IL-13 in allergy: home at last. Curr Opin Immunol 1999; 11 (6): 610-4
74. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-38
75. Chomarat P, Banchereau J. An update on interleukin-4 and its receptor. Eur Cytokine Netw 1997; 8 (4): 333-44
76. Miloux B, Laurent P, Bonnin O, et al. Cloning of the human IL-13R alpha 1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett 1997; 401 (2-3): 163-6
77. Callard RE, Matthews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol Today 1996; 17 (3): 108-10
78. Kotowicz K, Callard RE, Friedrich K, et al. Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor. Int Immunol 1996; 8 (12): 1915-25
79. Murata T, Obiri NI, Puri RK. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997; 70 (2): 230-40
80. Murata T, Obiri NI, Debinski W, et al. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997; 238 (1): 90-4
81. Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996; 156 (8): 2972-8
82. Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998; 91 (10): 3884-91
83. Obiri NI, Murata T, Debinski W, et al. Modulation of interleukin (IL)-13 binding and signaling by the gammac chain of the IL-2 receptor. J Biol Chem 1997; 272 (32): 20251-8
84. Obiri NI, Leland P, Murata T, et al. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 1997; 158 (2): 756-64
85. Vita N, Lefort S, Laurent P, et al. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J Biol Chem 1995; 270 (8): 3512-7
86. Zhang JG, Hilton DJ, Willson TA, et al. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein: evidence that it is distinct from the cloned II-13 receptor and II-4 receptor alpha-chains. J Biol Chem 1997; 272 (14): 9474-80
87. Gavett SH, O'Hearn DJ, Karp CL, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol 1997; 272 (2 Pt 1): L253-61
88. Malabarba MG, Rui H, Deutsch HH, et al. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J 1996; 319 (Pt 3): 865-72
89. van der Pouw Kraan TC, van Veen A, Boeije LC, et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1999; 1 (1): 61-5
90. Suzuki I, Hizawa N, Yamaguchi E, et al. Association between a C+33T polymorphism in the IL-4 promoter region and total serum IgE levels. Clin Exp Allergy 2000; 30 (12): 1746-9
91. Graves PE, Kabesch M, Halonen M, et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000; 105 (3): 506-13
92. Chouchane L, Sfar I, Bousaffara R, et al. A repeat polymorphism in interleukin-4 gene is highly associated with specific clinical phenotypes of asthma. Int Arch Allergy Immunol 1999; 120 (1): 50-5
93. Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997; 337 (24): 1720-5
94. Mitsuyasu H, Izuhara K, Mao XQ, et al. Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet 1998; 19 (2): 119-20
95. Mitsuyasu H, Yanagihara Y, Mao XQ, et al. Cutting edge: dominant effect of Ile50Val variant of the human IL-4 receptor alpha-chain in IgE synthesis. J Immunol 1999; 162 (3): 1227-31
96. Borish LC, Nelson HS, Correa J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107 (6): 963-70
97. Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994; 266 (5187): 1042-5
98. Thomis DC, Berg LJ. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med 1997; 185 (2): 197-206
99. Oakes SA, Candotti F, Johnston JA, et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 1996; 5 (6): 605-15
100. Wang LH, Kirken RA, Yang XY, et al. Selective disruption of interleukin 4 autocrine-regulated loop by a tyrosine kinase inhibitor restricts activity of T-helper 2 cells. Blood 2000; 95 (12): 3816-22
101. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 (14): 1038-42
102. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14): 1031-7
103. Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108 (2): 175-83